CREATING A FUTURE WORTH LIVING. FOR PATIENTS. WORLDWIDE. EVERY DAY.

Xenios AG - a company of the Fresenius Medical Care Group - is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer a wide range of heart and lung support products via a single platform, the Xenios console. 


Xenios’ mission is to improve patient well-being and care. The Novalung therapy aims at a paradigm shift in lung support: enabling the treatment of patients that are more awake, more self-determined and more mobile.


Xenios AG has been part of Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease since the end of 2016. Xenios complements the group's portfolio in the area of holistic multi-organ support of FME.

  


SOLUTIONS FOR LUNG FAILURE

Novalung offers solutions for the treatment of acute and chronic lung failure with a complete product portfolio for extrapulmonary lung assist. From neonates to adults.

 
FROM CO2 REMOVAL TO FULL OXYGENATION

NOVALUNG THERAPIES

The Novalung product family enables therapies for lung failure that are adapted to specific indications. In short, Novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The Novalung platform performs any level of CO2 removal and oxygenation in acute respiratory failure / AECOPD. 

 
 
SOLUTIONS FOR CARDIAC SURGEONS AND PERFUSIONISTS
Medos is your partner experienced in cardiopulmonary solutions for more than 30 years: Highly skilled employees and high quality manufacturing – for the benefit of cardiac surgeons, perfusionists and patients. Whether aortic valve replacement or bypass surgery, almost all cardiac surgery procedures can be performed effectively using Medos products. The acquisition of Medos and its established blood pump technology allowed Xenios to expand ist overall product and therapie portfolio.
 
OVER 30 YEARS OF EXPERIENCE
Medos focuses on the continuous development of therapy solutions for cardiac surgeons and perfusionists.

Products

Events

News

ICU Management

Xenios AG Announces Changes in the Management Board

2021 31 Mar

The Management Board of Xenios AG , the Heart & Lung Business Unit of Fresenius Medical Care, has been restructured. Effective January 31, 2021, the previous Chair of the Executive Board, Dr. Andreas Terpin, has left the company. The new senior trio on the Management Board will continue Fresenius Medical Care's success in the field of extracorporeal... Read more

ICU Management

iLA Membrane Ventilator Enables 36-Year-Old Woman To Survive 143 Days Until Lung Transplantation

2020 31 Aug

Doctors from General University Hospital in Prague saved the life of a 36-year-old woman and mother of a two-year-old child who urgently needed a lung transplant. She survived an incredible 143 days without a full working lung — due to the support of a device called iLA Membrane Ventilator. The iLA Membrane Ventilator is an extracorporeal ventilation... Read more

ICU Management

ECMO becomes crucial therapy in battle against COVID-19 in Europe - Xenios consoles as lifesavers

2020 30 Apr

As the coronavirus spreads and infections with COVID-19 further increase throughout Europe, ECMO therapy turns out to be a necessary option for patients with severe courses.    Xenios AG , a subsidiary of Fresenius Medical Care, provides ECMO consoles that can be used for the treatment of patients who develop severe pneumonia and ARDS with lung... Read more

ICU Management

Novalung System Receives US FDA Clearance

2020 26 Feb

The US FDA (Food and Drug Administration) has granted 510(k) approval to Fresenius Medical Care North America and Xenios, a Fresenius Medical Care company, for long-term use of its Novalung system for patients with acute lung failure or acute cardiopulmonary failure. The FDA announced this on Friday evening. With class II approval, the Novalung... Read more

ICU Management

Merger: Novalung Becomes Fully Integrated within Xenios

2019 02 Sep

Novalung GmbH, which specialises in solutions for respiratory failure, was absorbed into Xenios AG on 30 August 2019. Processes will be streamlined as a result and the company will become more closely aligned with the parent company Fresenius Medical Care. Novalung was established in 2003 and specialises in the treatment of respiratory failure.... Read more

ICU Management

Synchronised Cardiovascular Support Now Ready for the Market

2019 10 Jul

Xenios AG concludes its first clinical study on i-cor Synchronized Cardiac Assist, documenting the safety and feasibility of the synchronized cardiovascular support system. During the “SynCor” trial, a multicentre study treated 47 patients in nine different German clinics using an innovative pulsatile, cardiac-synchronous circulatory support... Read more

ICU Management

Relaunch of the Xenios Website – Now harmonised with that of its parent, Fresenius Medical Care

2019 08 May

The Xenios AG, pioneer in extracorporeal heart and lung support, has restructured its website. Xenios AG has been part of the Fresenius Medical Care Group since 2016 and the new design also serves to bring the company visually in line with the brand image of its parent.   www.xenios-ag.com   With this newly structured website, the... Read more

ICU Management

Six Days Without a Lung – a Look into the Future of Medical Technology

2017 12 Apr

The dramatic story of Canadian Melissa Benoit, who lived for six days without a lung, shows a view of a new chapter in the history of medical technology. The novalung iLA membrane lung, which replaced the functions of the lung, is a product of XENIOS AG. As a strategic partner of XOR Labs in Toronto, both companies wanted to cooperate to revolutionize... Read more

Jobs not available

Catalogue


http://www.xenios-ag.com
[email protected]
Im Zukunftspark, 1
Heilbronn
74076
Germany
+49 7131 2706 0

White Papers - Case Studies

Not available

Videos

Articles

Not available

Blog

Not available

XENIOS CAMPUS

JOIN – LEARN – CARE

Join the Xenios Campus, the online platform for clinical support, information, training and continuing training – putting the emphasis on blended learning.

The Xenios Campus knows the value of having the right knowledge. It offers innovative modules that enable you to pursue individual advanced training.